Valuation: Amicus Therapeutics

Market Cap 4.55B 4.13B 3.82B 3.45B 6.51B 427B 6.74B 45.93B 18.2B 229B 17.07B 16.71B 726B P/E 2024
-51.1x
P/E 2025 -162x
Enterprise Value 4.7B 4.27B 3.94B 3.56B 6.72B 441B 6.96B 47.43B 18.79B 237B 17.63B 17.26B 750B EV / Sales 2024
5.69x
EV / Sales 2025 7.18x
Free-Float
99.31%
Yield 2024 *
-
Yield 2025 -
Change 5-day change 1-year change 3-year change Capi.($)
+1.57%+1.65% - - 4.55B
-1.29%-1.76%+51.98%+64.66% 66.33B
-0.09%+2.79%+10.75%+95.02% 60.62B
+0.63%+1.64%+24.25%+89.70% 55.5B
-0.67%-0.49%+10.26%+119.53% 47.58B
-0.16%-5.29%+22.20%+28.96% 43.69B
-2.61%-15.91%+143.43%+692.05% 37.27B
+0.23%+1.66%+14.85%+49.06% 36.57B
+2.35%-3.61%+78.64%+60.70% 32.22B
+2.59%+6.84%-37.16%+407.53% 26.58B
Average +0.28%+0.33%+35.47%+178.58% 45B
Weighted average by Cap. -0.05%+0.33%+35.28%+153.44%

Financials

2024 2025
Net sales 528M 480M 443M 401M 756M 49.6B 783M 5.33B 2.11B 26.62B 1.98B 1.94B 84.32B 634M 576M 532M 481M 907M 59.55B 939M 6.4B 2.54B 31.96B 2.38B 2.33B 101B
Net income -56.11M -50.97M -47.1M -42.54M -80.28M -5.27B -83.1M -566M -224M -2.83B -211M -206M -8.95B -27.11M -24.63M -22.76M -20.56M -38.79M -2.55B -40.16M -274M -108M -1.37B -102M -99.58M -4.33B
Net Debt 194M 176M 163M 147M 277M 18.19B 287M 1.96B 775M 9.76B 727M 711M 30.92B 149M 135M 125M 113M 213M 13.97B 220M 1.5B 595M 7.5B 558M 547M 23.75B
Logo Amicus Therapeutics
Amicus Therapeutics, Inc. is a global biotechnology company focused on discovering, developing and delivering medicines for people living with rare diseases. Its two marketed therapies are Galafold, the first oral monotherapy for people living with Fabry disease who have amenable genetic variants, and Pombiliti + Opfolda, a two-component treatment for adults living with late-onset Pompe disease. As an orally miglustat monotherapy, Galafold is designed to bind to and stabilize an endogenous alpha-galactosidase A enzyme in those patients with genetic variants identified as amenable in a Good Laboratory Practice cell-based amenability assay. Pombiliti + Opfolda consists of an engineered rhGAA enzyme, cipaglucosidase alfa-atga, with an optimized carbohydrate structure to enhance cellular uptake, administered intravenously in combination with orally administered miglustat. In addition, clinical studies are ongoing in pediatric patients for both the LOPD and IOPD populations.
Employees
-